These data encourage further studies aimed at testing D16F7 effectiveness in metastatic tumor models as a single agent or in combination with antiangiogenic agents targeting VEGF-A/VEGFR-2 signaling or immune checkpoint inhibitors. The gene discussed is KDR; the disease is metastatic neoplasm.